IPO STREAM
FIRST IN WINS
POST HOLIDAY GAINS
ARE UPON US!
Week of July 13 – 17, 2026 · ipostream.com
4 IPOs This Week · Tech · Nuclear Energy · Ticketing · Biotech · Published July 13, 2026July 13, 2026
Good morning all! We're putting together a fresh overview of this week's IPOs — highlighting the companies, their expected pricing, deal sizes, and why we believe each one stands out. Let's get right to it.
Here we are post-holiday and things are heating up. Expect this to continue — the market is ripe for gains.
THIS WEEK AT A GLANCE
| Company |
Ticker |
Raise |
Price Range |
Lead Banks |
| Csquare |
CSQR |
~$1.25B |
$23–$27 |
MS, JPM, BofA + |
| Standard Nuclear |
STDN |
~$356M |
$18–$21 |
BofA, Goldman Sachs + |
| Ticketplus |
TP |
~$25M |
$13–$15 |
Bancroft, Roth, MDB |
| Tarsier Pharma |
TARX |
~$45M |
$8–$10 |
Konik Capital |
FULL BREAKDOWN
The Big One This Week · Massive Syndicate
|
Csquare
CSQR
|
Technology / Enterprise
|
|
Raise / Price
~$1.25B @ $23–$27
|
Lead Underwriters
Morgan Stanley, J.P. Morgan
BofA + others
|
Type
Sizable tech or
enterprise play
|
The anchor deal of the week at $1.25B — massive syndicate including Morgan Stanley, J.P. Morgan, and BofA. When all three of those heavyweights show up together to a billion-dollar deal, it's a clear signal that institutional demand is strong. This one anchors the week's activity.
Nuclear Renaissance · AI Data Center Power Demand
|
Standard Nuclear
STDN
|
Nuclear Energy
|
|
Raise / Price
~$356M @ $18–$21
|
Lead Underwriters
BofA, Goldman Sachs
+ strong group
|
Tailwind
AI power demand +
energy transition
|
Nuclear energy is having a major moment — AI data centers need reliable, clean power around the clock, and nuclear is the only source that can deliver it at scale. BofA and Goldman Sachs leading a $356M raise with a strong group.
Timing feels spot-on for today's energy transition and tech infrastructure boom. This is the AI infrastructure play that most investors overlook.
Live Events Boom · LatAm Growth Market
|
Ticketplus
TP
|
Live Events / LatAm
|
|
Raise / Price
~$25M @ $13–$15
|
Underwriters
Bancroft Capital
Roth Capital · MDB Capital
|
Market
Latin America
Ticketing + Event SaaS
|
A Latin American live event ticketing platform and event software provider raising $25M at $13–$15. The live events market is booming post-pandemic, and their LatAm focus gives them exposure to a young, growing population hungry for concerts and sports. Could catch fire if they show strong growth in ticket sales and international expansion.
Phase 3 · Steroid-Free Approach · Previously Delayed
|
Tarsier Pharma
TARX
Israel-based
|
Ophthalmology Biotech
|
|
Raise / Price
~$45M @ $8–$10
|
Underwriter
Konik Capital Partners
|
Lead Drug
TRS01 — Phase 3
Non-infectious uveitis
|
This one has previously set its debut and then revoked it due to market conditions — now it's back with a firmer pricing. Developing steroid-free treatments for serious eye inflammation that can lead to blindness. Lead drug TRS01 is in Phase 3.
Eye disease therapies have huge unmet needs — avoiding steroids means fewer side effects, a real clinical advantage. Healthcare innovation with an aging population driving demand. High-risk, high-reward specialty pharma play.
Here we are post-holiday and things are heating up. Expect this to continue. The market is ripe for gains.
